scispace - formally typeset
H

Hiroaki Shimokawa

Researcher at Tohoku University

Publications -  976
Citations -  56856

Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.

Papers
More filters
Journal ArticleDOI

Transforming Growth Factor-β2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases: Possible Involvement of Hyalocytes and Therapeutic Potential of Rho Kinase Inhibitor

TL;DR: Combined effects of TGF-beta2 and CTGF appear to be involved in the pathogenesis of proliferative vitreoretinal diseases and Hyalocytes may be a possible source of CTGF and thus might play a role in vit reoretinal interface diseases.
Journal ArticleDOI

Pathogenic Role of Oxidative Stress in Vascular Angiotensin-Converting Enzyme Activation in Long-Term Blockade of Nitric Oxide Synthesis in Rats

TL;DR: The results implicate oxidative stress in the pathogenesis of vascular ACE activation in rats with long-term inhibition of NO synthesis and the observed effects of antioxidant drugs on ACE activation do not appear to involve the hypertension induced by L-NAME.
Journal ArticleDOI

Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms

TL;DR: These results provide the first direct evidence that genetic disruption of the whole NOS system causes spontaneous myocardial infarction associated with multiple cardiovascular risk factors of metabolic origin in mice in vivo through the angiotensin II type 1 receptor pathway.
Journal ArticleDOI

Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Protein Kinase C

TL;DR: Transient preischemic activation of PKA reduces infarct size through Rho-kinase inhibition and actin cytoskeletal deactivation during sustained ischemia, implicating a novel mechanism for cardioprotection by ischemic preconditioning independent of PKC and a potential new therapeutic target.